@article{PAR00021521,
  title = {{O}utcomes of 3,737 {COVID}-19 patients treated with hydroxychloroquine/azithromycin and other regimens in {M}arseille, {F}rance : a retrospective analysis},
  author = {{L}agier, {J}. {C}. and {M}illion, {M}. and {G}autret, {P}. and {C}olson, {P}. and {C}ortaredona, {S}{\'e}bastien and {G}iraud-{G}atineau, {A}. and {H}onore, {S}. and {G}aubert, {J}. {Y}. and {F}ournier, {P}. {E}. and {T}issot-{D}upont, {H}. and {C}habriere, {E}. and {S}tein, {A}. and {D}eharo, {J}.{C}. and {F}enollar, {F}. and {R}olain, {J}. {M}. and {O}badia, {Y}. and {J}acquier, {A}. and {L}a {S}cola, {B}. and {B}rouqui, {P}. and {D}rancourt, {M}. and {P}arola, {P}. and {R}aoult, {D}. and {IHU} {COVID}-19 {T}ask {F}orce},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {I}n our institute in {M}arseille, {F}rance, we initiated early and massive screening for coronavirus disease 2019 ({COVID}-19). {H}ospitalization and early treatment with hydroxychloroquine and azithromycin ({HCQ}-{AZ}) was proposed for the positive cases. {M}ethods: {W}e retrospectively report the clinical management of 3,737 screened patients, including 3,119 (83.5%) treated with {HCQ}-{AZ} (200 mg of oral {HCQ}, three times daily for ten days and 500 mg of oral {AZ} on day 1 followed by 250 mg daily for the next four days, respectively) for at least three days and 618 (16.5%) patients treated with other regimen ("others"). {O}utcomes were death, transfer to the intensive care unit ({ICU}), >= 10 days of hospitalization and viral shedding. {R}esults: {T}he patients' mean age was 45 (sd 17) years, 45% were male, and the case fatality rate was 0.9%. {W}e performed 2,065 low-dose computed tomography ({CT}) scans highlighting lung lesions in 592 of the 991 (59.7%) patients with minimal clinical symptoms ({NEWS} score = 0). {A} discrepancy between spontaneous dyspnoea, hypoxemia and lung lesions was observed. {C}linical factors (age, comorbidities, {NEWS}-2 score), biological factors (lymphocytopenia; eosinopenia; decrease in blood zinc; and increase in {D}-dimers, lactate dehydrogenase, creatinine phosphokinase, troponin and {C}-reactive protein) and moderate and severe lesions detected in low-dose {CT} scans were associated with poor clinical outcome. {T}reatment with {HCQ}-{AZ} was associated with a decreased risk of transfer to {ICU} or death ({H}azard ratio ({HR}) 0.18 0.11-0.27), decreased risk of hospitalization >= 10 days (odds ratios 95% {CI} 0.38 0.27-0.54) and shorter duration of viral shedding (time to negative {PCR}: {HR} 1.29 1.17-1.42). {QT}c prolongation (>60 ms) was observed in 25 patients (0.67%) leading to the cessation of treatment in 12 cases including 3 cases with {QT}c> 500 ms. {N}o cases of torsade de pointe or sudden death were observed. {C}onclusion: {A}lthough this is a retrospective analysis, results suggest that early diagnosis, early isolation and early treatment of {COVID}-19 patients, with at least 3 days of {HCQ}-{AZ} lead to a significantly better clinical outcome and a faster viral load reduction than other treatments.},
  keywords = {{SARS}-{C}o{V}-2 ; {COVID}-19 ; {H}ydroxychloroquine ; {A}zithromycin ; {FRANCE} ; {MARSEILLE}},
  booktitle = {},
  journal = {{T}ravel {M}edicine and {I}nfectious {D}isease},
  volume = {36},
  numero = {},
  pages = {101791 [11 p.]},
  ISSN = {1477-8939},
  year = {2020},
  DOI = {10.1016/j.tmaid.2020.101791},
  URL = {https://www.documentation.ird.fr/hor/{PAR}00021521},
}